(MedPage Today) — NEW ORLEANS – A single injection of a gene-edited protein was deemed productive and safe in patients with dyslipidemia that was unresponsive to lipid-lowering therapy, according to a phase I trial.
IV CTX310 is an in vivo…
Source link : https://www.medpagetoday.com/meetingcoverage/aha/118389
Author :
Publish date : 2025-11-08 16:38:00
Copyright for syndicated content belongs to the linked Source.
